Literature DB >> 6354567

Clinical usefulness of vancomycin.

B A Cunha, A M Ristuccia.   

Abstract

The antibacterial spectrum, pharmacokinetics, and clinical uses of vancomycin are reviewed. Vancomycin interferes with peptidoglycan biosynthesis in multiplying organisms and is bactericidal. It is supplied as the hydrochloride salt and is available in 500-mg ampuls. Vancomycin is usually administered intravenously or orally. I.V. vancomycin should be administered slowly (over 30--60 min) and in an adequate volume (100--250 ml) of 5% dextrose injection. Usual adult dose is 500 mg every six hours or 1 g every 12 hours. Serum vancomycin kinetics are best explained on the basis of a two- or three-compartment open model. Vancomycin is almost completely eliminated through the kidneys. Mean vancomycin concentrations in the presence of inflamed meninges, pleural fluid, pericardial fluid, ascitic fluid, synovial fluid, and bile are approximately 15% of the serum concentrations. Vancomycin is used prophylactically to prevent infections caused by gram-positive cocci. Vancomycin is an ideal drug for prophylaxis in prosthetic implant surgery because of its long serum half-life and activity against Staphylococcus epidermidis and Staph. aureus. Vancomycin has been used in the prevention and treatment of shunt infection in hemodialysis patients. It can be used adjunctly with a number of antibiotics to treat a variety of bacterial infections. Vancomycin is recognized as one of the most potent antistaphylococcal drugs available. It is the drug-of-choice in the treatment of serious methicillin-resistant Staph. aureus infections. It is the preferred therapy for Clostridium difficile (antibiotic-associated) colitis.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6354567

Source DB:  PubMed          Journal:  Clin Pharm        ISSN: 0278-2677


  8 in total

1.  Drug utilization review in a teaching hospital: experience with vancomycin.

Authors:  G M Misan; E D Martin; E R Smith; A A Somogyi; R C Bartholomeusz; F Bochner
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Vancomycin Serum Concentration Monitoring : The Middle Ground is Best.

Authors:  F Marra; B Cairns; P Jewesson
Journal:  Clin Drug Investig       Date:  1996-08       Impact factor: 2.859

3.  Pharmacokinetics of vancomycin in patients undergoing continuous ambulatory peritoneal dialysis.

Authors:  R D Blevins; C E Halstenson; N G Salem; G R Matzke
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

Review 4.  Vancomycin ototoxicity and nephrotoxicity. A review.

Authors:  G R Bailie; D Neal
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Sep-Oct

Review 5.  Clinical pharmacokinetics of vancomycin.

Authors:  G R Matzke; G G Zhanel; D R Guay
Journal:  Clin Pharmacokinet       Date:  1986 Jul-Aug       Impact factor: 6.447

6.  Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique.

Authors:  K Vance-Bryan; D R Guay; S S Gilliland; K A Rodvold; J C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

7.  Current pattern of antibiotic resistance of clinical isolates among conjunctival swabs.

Authors:  Farhan Essa Abdullah; Mariya Irfan Khan; Sadia Waheed
Journal:  Pak J Med Sci       Date:  2013-01       Impact factor: 1.088

8.  The importance of active learning and practice on the students' mastery of pharmacokinetic calculations for the intermittent intravenous infusion dosing of antibiotics.

Authors:  Reza Mehvar
Journal:  BMC Med Educ       Date:  2012-11-22       Impact factor: 2.463

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.